These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34139702)

  • 1. Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
    Krečak I; Lucijanić M
    Pharmacology; 2021; 106(7-8):451-452. PubMed ID: 34139702
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 3. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How should patients with essential thrombocythemia be treated?].
    Ikeda Y
    Rinsho Ketsueki; 2001 Jun; 42(6):447-51. PubMed ID: 11505520
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
    Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
    Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of essential thrombocythemia in childhood.
    Scherer S; Ferrari R; Rister M
    Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
    Birgegård G
    Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of essential thrombocythemia with anagrelide.
    Chintagumpala MM; Kennedy LL; Steuber CP
    J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 14. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B; Chai-Adisaksopha C; Garcia D
    J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathogenesis and management of essential thrombocythaemia.
    Green AR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():36-9. PubMed ID: 10907463
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Essential thrombocythemia: therapy with anagrelide].
    Mazzucconi MG; Ferrari A; Balduini CL
    Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.